Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TPE:1762's EV-to-FCF is ranked better than 54.72% of 318
companies
in the Biotechnology industry
Industry Median: 15.835
vs TPE:1762: 12.70
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Chunghwa Chemical Synthesis & Biotech Co's PE Ratio (TTM) for today is calculated as:
Chunghwa Chemical Synthesis & Biotech Co's share price for today is NT$35.80.
Chunghwa Chemical Synthesis & Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.930.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Chunghwa Chemical Synthesis & Biotech Co EV-to-FCF Related Terms
Chunghwa Chemical Synthesis & Biotech Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chunghwa Chemical Synthesis & Biotech Co EV-to-FCF Chart
Chunghwa Chemical Synthesis & Biotech Co Annual Data
TPE:1762 vs VRTX, REGN, MRNA: EV-to-FCF Comparison
For the Biotechnology subindustry, Chunghwa Chemical Synthesis & Biotech Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chunghwa Chemical Synthesis & Biotech Co EV-to-FCF vs Biotechnology Industry
Chunghwa Chemical Synthesis & Biotech Co's current Enterprise Value is NT$3,187.0 Mil.
Chunghwa Chemical Synthesis & Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$248.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) has a EV-to-FCF of 12.83 as of Sep. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. This is near median its historical median of 11.92. According to the industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #144 out of 318 companies in the Biotechnology industry, placing it in the top 45.3%.
Is Chunghwa Chemical Synthesis & Biotech Co's EV-to-FCF too high?
Chunghwa Chemical Synthesis & Biotech Co's current EV-to-FCF of 12.83 is near median its 10-year median of 11.92. The Biotechnology industry median EV-to-FCF is 15.84. Chunghwa Chemical Synthesis & Biotech Co's value of 12.83 is 19% below this industry median. Based on the distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #144 out of 318 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Chunghwa Chemical Synthesis & Biotech Co has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chunghwa Chemical Synthesis & Biotech Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #144 out of 318 companies for EV-to-FCF. This puts Chunghwa Chemical Synthesis & Biotech Co in the upper half of its industry. The industry median EV-to-FCF is 15.84. Chunghwa Chemical Synthesis & Biotech Co's value of 12.83 is 19% below this benchmark. While the company's 10-year median is 11.92 vs. the industry median of 15.84, Chunghwa Chemical Synthesis & Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.84, based on 318 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chunghwa Chemical Synthesis & Biotech Co's current EV-to-FCF of 12.83 is 19% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chunghwa Chemical Synthesis & Biotech Co's current EV-to-FCF is 12.83, which is near median its own 10-year median of 11.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chunghwa Chemical Synthesis & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) is currently considered Fairly Valued. The stock's GF Value™ is NT$36.94, compared to a current price of NT$35.80 — trading 3.1% below its estimated fair value. The current EV-to-FCF is 12.83, which is near median its 10-year median of 11.92 and 19% below the Biotechnology industry median of 15.84. Chunghwa Chemical Synthesis & Biotech Co's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Chunghwa Chemical Synthesis & Biotech Co (TPE:1762), the current EV-to-FCF is 12.83 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Overvalued in 2026?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co stock appears to be undervalued.
The current stock price of NT$35.80 is trading 3.1% below its estimated GF Value™ of NT$36.94.
GuruFocus considers Chunghwa Chemical Synthesis & Biotech Co to be Fairly Valued.
Key valuation signals for TPE:1762:
EV-to-FCF: 12.83 (near median its 10-year median of 11.92)
GF Value™: NT$36.94 vs. price of NT$35.80 (3.1% below fair value)
Industry Position: 19% below the Biotechnology median (#144 of 318)
No single metric tells the full story. See the TPE:1762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chunghwa Chemical Synthesis & Biotech Co Ltd is engaged in the research, development, manufacturing, and sales of pharmaceutical products. Geographically, it derives a majority of its revenue from the United States and also has a presence in Taiwan. Its product portfolio comprises pain management, antifungal, immunosuppressant, oncology, Cardiovascular, Peptide Drugs, and Others.
66GF Score
Get the complete analysis for TPE:1762
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1762 has been successfully added to your 
